1. Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor.
- Author
-
Kernt M, Liegl RG, Rueping J, Neubauer AS, Haritoglou C, Lackerbauer CA, Eibl KH, Ulbig MW, and Kampik A
- Subjects
- Adult, Aged, Astrocytes drug effects, Astrocytes radiation effects, Benzenesulfonates therapeutic use, Cell Survival drug effects, Cell Survival radiation effects, Humans, Light adverse effects, Middle Aged, Niacinamide analogs & derivatives, Optic Disk immunology, Optic Disk metabolism, Optic Disk radiation effects, Phenylurea Compounds, Placenta Growth Factor, Platelet-Derived Growth Factor biosynthesis, Pregnancy Proteins biosynthesis, Protein Kinase Inhibitors therapeutic use, Pyridines therapeutic use, Retina metabolism, Retina radiation effects, Retinal Neovascularization drug therapy, Sorafenib, Vascular Endothelial Growth Factor A biosynthesis, Benzenesulfonates pharmacology, Optic Disk drug effects, Platelet-Derived Growth Factor antagonists & inhibitors, Pregnancy Proteins antagonists & inhibitors, Protein Kinase Inhibitors pharmacology, Pyridines pharmacology, Retina drug effects, Vascular Endothelial Growth Factor A antagonists & inhibitors
- Abstract
Objectives: Growth factors, such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and placenta growth factor (PlGF) are key players in the development of diabetic retinopathy, age-related macular degeneration, and other retinal neovascular diseases. Glial cells provide a significant source of retinal growth factor production under physiologic and pathologic conditions. Cumulative light exposure has been linked to increased retinal growth factor expression. Previous reports indicate that sorafenib, an oral multikinase inhibitor, might have a beneficial effect on retinal neovascularization. This study was designed to investigate the effects of sorafenib on light-induced overexpression of growth factors in human retinal glial cells., Methods: Primary human optic nerve head astrocytes (ONHAs) were exposed to white light and incubated with sorafenib. Viability, expression, and secretion of VEGF-A, PDGF-BB, and PlGF and their mRNA were determined by reverse transcription-polymerase chain reaction, immunohistochemistry, and enzyme-linked immunosorbent assay., Results: Light exposure decreased cell viability and increased VEGF-A, PDGF-BB, and PlGF expression and secretion. These light-induced effects were significantly reduced when cells were treated with sorafenib at a concentration of 1 microg/ml., Conclusion: Sorafenib significantly reduced light-induced overexpression of VEGF-A, PDGF-BB, and PlGF in primary human ONHAs. Sorafenib has promising properties as a potential supportive treatment for retinal neovascularization.
- Published
- 2010
- Full Text
- View/download PDF